A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction

Cardiac Catheterization Laboratory, University of Michigan Medical Center, Ann Arbor 48109-0688.

The adjunctive use of intravenous captopril with tissue plasminogen activator early during acute myocardial infarction offers theoretic advantages of diminishing left ventricular volume, preventing ventricular dilation and improving patient survival. To test the safety and efficacy of combined early administration of intravenous captopril and recombinant tissue-type plasminogen activator (rt-PA), 38 patients treated with rt-PA 3 +/- 0.3 h (mean +/- SE) after the onset of myocardial infarction were randomized to intravenous followed by oral captopril or placebo therapy. They underwent cardiac catheterization with measurement of hemodynamic variables and left ventricular function and determination of serum renin, angiotensin and aldosterone levels on days 1 and 7. Oral administration of the selected agent was continued for 3 months along with other antianginal medications, including nonangiotensin-converting enzyme inhibitor vasodilators. Repeat measurements of left ventricular function were obtained before hospital discharge and at 3 months. There were no significant differences in baseline clinical characteristics between groups. One patient in the captopril-treated group became hypotensive during intravenous therapy, requiring discontinuation of treatment. Compared with the placebo-treated group, the captopril-treated group had significant reductions at day 7 in left ventricular end-diastolic pressure (22.5 +/- 1.5 versus 16.3 +/- 1.6 mm Hg, p less than 0.01) and mean systemic arterial pressure (93.6 +/- 3.3 versus 86.2 +/- 2.7 mm Hg, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]

				M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF]

				J. Galcera-Tomas, F. J. Castillo-Soria, M. Villegas-Garcia, R. Florenciano-Sanchez, J. G. Sanchez-Villanueva, J. A. N. de la Rosa, A. Martinez-Caballero, J. A. Valenti-Aldeguer, P. Jara-Perez, M. Parraga-Ramirez, et al. Effects of Early Use of Atenolol or Captopril on Infarct Size and Ventricular Volume : A Double-Blind Comparison in Patients With Anterior Acute Myocardial Infarction Circulation, February 13, 2001; 103(6): 813 - 819. [Abstract] [Full Text] [PDF]

				P. J. de Kam, A. A. Voors, M. P. van den Berg, D. J. van Veldhuisen, J. Brouwer, H. J. G. M. Crijns, C. Borghi, E. Ambrosioni, J. S. Hochman, T. H. LeJemtel, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a meta-analysis of 845 patients J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2047 - 2053. [Abstract] [Full Text] [PDF]

				H. Oxenham and N. Sharpe Angiotensin-converting enzyme inhibitor treatment after myocardial infarction: A selective approach for maximum benefit J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2054 - 2055. [Full Text] [PDF]

				M. J. Domanski, D. V. Exner, C. B. Borkowf, N. L. Geller, Y. Rosenberg, and M. A. Pfeffer Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials J. Am. Coll. Cardiol., March 1, 1999; 33(3): 598 - 604. [Abstract] [Full Text] [PDF]

				M. A. Pfeffer ACE Inhibitors in Acute Myocardial Infarction : Patient Selection and Timing Circulation, June 9, 1998; 97(22): 2192 - 2194. [Full Text] [PDF]

				Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction : Systematic Overview of Individual Data From 100 000 Patients in Randomized Trials Circulation, June 9, 1998; 97(22): 2202 - 2212. [Abstract] [Full Text] [PDF]

				M. Oosterga, A. A. Voors, P.-J. de Kam, H. Schunkert, Y. M. Pinto, J. H. Kingma, and W. H. van Gilst Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction Circulation, June 17, 1997; 95(12): 2607 - 2609. [Abstract] [Full Text]

				M. A. Pfeffer, S. C. Greaves, J. M. O. Arnold, R. J. Glynn, F. S. LaMotte, R. T. Lee, F. J. Menapace Jr, E. Rapaport, P. M. Ridker, J.-L. Rouleau, et al. Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction : The Healing and Early Afterload Reducing Therapy Trial Circulation, June 17, 1997; 95(12): 2643 - 2651. [Abstract] [Full Text]

				R. N. Piana, S. Y. Wang, M. Friedman, and F. W. Sellke Angiotensin-Converting Enzyme Inhibition Preserves Endothelium-Dependent Coronary Microvascular Responses During Short-term Ischemia-Reperfusion Circulation, February 1, 1996; 93(3): 544 - 551. [Abstract] [Full Text]

				M. Testa, E. H. Sonnenblick, and T. H. LeJemtel Dr. Practical Issues for the Use of ACE Inhibitors in Acute Myocardial Infarction European Journal of Cardiovascular Prevention & Rehabilitation, October 1, 1995; 2(5): 429 - 433. [Abstract] [PDF]